Search Results

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK) today announced that results of its preclinical studies on ATG-101 (PD-L1/4-1BB bispecific antibody) were published in Cancer Research in a paper titled ATG-101 is a tetravalent PD-L1×4-1BB bispecific antibody that stimulates anti-tumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation[1].

JCR Pharmaceuticals’ Research Presentations at WORLD Symposium ™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders.

Nanjing Leads Biolabs Co., Ltd. announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to conduct the single-arm pivotal study for registration and market authorization from the Center for Drug Evaluation of the National Medical Products Administration.

Medigene AG announces that the Company has been issued a patent by the European Patent Office protecting its PD1-41BB costimulatory switch protein technology.

Medigene AG presents an overview on elevated activity of T cell receptor engineered T cell therapies when combining Medigene´s PD1-41BB switch receptor with T cell receptors targeting different antigens at the Immuno-Oncology Summit Europe June 20-22, 2023 in London, UK.

Medigene AG presents data showing significantly enhanced T cell activity when combining the PD1-41BB costimulatory switch protein with recombinant T cell receptors not only when directed at the cancer-testis antigen New York esophageal squamous cell carcinoma-1 /L Antigen Family Member-1a, but also, presented here for the first time, against the neoantigen mutant Kirsten rat sarcoma virus G12V at the ESMO Congress 2023 held October 20-24, 2023, in Madrid, Spain.

The annual meeting of the American Society of Clinical Oncology commenced on May 31st, Showcasing groundbreaking cancer research from around the world.